Download video

Tian Zhang, MD, on the evolving landscape of metastatic hormone-sensitive prostate cancer

77 views

OBRoncology

5 years ago

Tian Zhang, MD, on the evolving landscape of metastatic hormone-sensitive prostate cancer

Tian Zhang, MD, on the evolving landscape of metastatic hormone-sensitive prostate cancer

Tian Zhang, MD, on the evolving landscape of metastatic hormone-sensitive prostate cancer
1:17
Tian Zhang, MD, on the evolving landscape of metastatic hormone-sensitive prostate cancer
by OBRoncology
Dr. Zhang on the ARCHES Trial in Prostate Cancer
1:03
Dr. Zhang on the ARCHES Trial in Prostate Cancer
by OncLive
Tian Zhang, MD, discusses the most anticipated trial results regarding biomarkers in RCC
1:28
Tian Zhang, MD, discusses the most anticipated trial results regarding biomarkers in RCC
by OBRoncology
Tian Zhang, MD, on predictive biomarkers in selecting patient populations for I-O treatment in RCC
1:45
Tian Zhang, MD, on predictive biomarkers in selecting patient populations for I-O treatment in RCC
by OBRoncology
Che-Kai Tsao, MD, regarding the evolving landscape of metastatic clear cell RCC
2:28
Che-Kai Tsao, MD, regarding the evolving landscape of metastatic clear cell RCC
by OBRoncology
Characterization of circulating immune cells in metastatic urothelial cancer following treatment
2:25
Characterization of circulating immune cells in metastatic urothelial cancer following treatment
by VJOncology
Tian Zhang, MD, regarding strategies for treating RCC in the 2nd line setting
1:22
Tian Zhang, MD, regarding strategies for treating RCC in the 2nd line setting
by OBRoncology
Dr. Zhang on Toxicities of Treatments in RCC
1:11
Dr. Zhang on Toxicities of Treatments in RCC
by OncLive
Tian Zhang, MD, offers perspective on treating newly diagnosed RCC patients
1:21
Tian Zhang, MD, offers perspective on treating newly diagnosed RCC patients
by OBRoncology
Concordance of different PD-L1 assays: expression in bladder and kidney cancer
2:50
Concordance of different PD-L1 assays: expression in bladder and kidney cancer
by VJOncology
GU ASCO 2024 Highlights with Dr. Tian Zhang – CONTACT-02, BRCAAway, AMBASSADOR, Keynote-564
17:46
GU ASCO 2024 Highlights with Dr. Tian Zhang – CONTACT-02, BRCAAway, AMBASSADOR, Keynote-564
by OncBrothers: Practice-Changing Cancer Discussions
Tian Zhang, MD, elaborates on the PEDIGREE clinical study in advanced renal cell cancer patients
1:58
Tian Zhang, MD, elaborates on the PEDIGREE clinical study in advanced renal cell cancer patients
by OBRoncology
Che-Kai Tsao, MD, elaborates on results from the TITAN study in mCRPC from ASCO '19
0:55
Che-Kai Tsao, MD, elaborates on results from the TITAN study in mCRPC from ASCO '19
by OBRoncology
What are the latest in ADCs for prostate and bladder cancer?
2:19
What are the latest in ADCs for prostate and bladder cancer?
by VJOncology
Dr. Zhang on the Impact of the LATITUDE Study in Prostate Cancer
1:32
Dr. Zhang on the Impact of the LATITUDE Study in Prostate Cancer
by OncLive
AUAU Podcast: Treatment For Metastatic Hormone Sensitive Prostate Cancer
23:29
AUAU Podcast: Treatment For Metastatic Hormone Sensitive Prostate Cancer
by AUAUniversity
Identifying predictive markers for checkpoint inhibitor response in kidney cancer
1:34
Identifying predictive markers for checkpoint inhibitor response in kidney cancer
by VJOncology
Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting
0:54
Tian Zhang, MD, explains how to treat mRCC after combination I-O in the 1st line setting
by OBRoncology
GU Cast | Six big things in metastatic prostate cancer 2022
33:38
GU Cast | Six big things in metastatic prostate cancer 2022
by GU Cast
Prostate Cancer Outcomes After Ga68-PSMA-PET Imaging
6:55
Prostate Cancer Outcomes After Ga68-PSMA-PET Imaging
by GU Oncology Now